Inflammatory Bowel Disease
Filter News
Found 47 articles
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract. -
OstoBuddy and South Asian IBD Alliance Named Winners of Innovation Challenge, in Collaboration with Bristol Myers Squibb, to Address Unmet Needs in Inflammatory Bowel Disease
1/26/2023
Lyfebulb is pleased to announce the winners for the Innovation Challenge "Addressing Unmet Needs in IBD" in collaboration with Bristol Myers Squibb.
-
Inotrem Receives Funding From the Crohn’s & Colitis Foundation to Help Develop New Therapeutic Approaches in Inflammatory Bowel Disease (IBD)
1/9/2023
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD.
-
GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
8/10/2022
GentiBio, Inc., an engineered regulatory T cells (Tregs) company, announced today that it has entered into a collaboration with Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).
-
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
6/28/2022
BiomX Inc. announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease.
-
Ferring Announces New Collaboration for Development of Olamkicept
6/9/2022
Strategic collaboration to further develop olamkicept highlights Ferring’s continued commitment to innovation in gastroenterology and inflammatory bowel disease.
-
Pfizer and Eli Lilly are forging ahead with ulcerative colitis (UC) research after posting positive results from their respective Phase III studies. -
Iterative Scopes DDW Presentation Shows Accuracy of Automated Endoscopic Disease Scoring Model, With Potential to Accelerate IBD Clinical Trials
5/24/2022
Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced today that data presented at Digestive Disease Week (DDW) 2022 show that the company’s proprietary machine learning model accurately and consistently predicts scoring of endoscopic disease severity in ulcerative colitis (UC), a common type of inflammatory bowel disease (IBD).
-
Organovo Achieves 3D Tissue Model for Crohn’s Disease
5/17/2022
Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has successfully advanced its first inflammatory bowel disease (IBD) model to the next step of target discovery and validation for Crohn’s disease.
-
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of IBD
5/16/2022
Surrozen, Inc. announced the publication of an article by Surrozen scientists in the journal Cellular and Molecular Gastroenterology and Hepatology.
-
Emulate Announces Launch of Immune Cell Recruitment Application for the Colon Intestine-Chip to Aid in the Study of Inflammatory Bowel Disease
5/9/2022
Emulate, Inc. today announced its new colon immune cell recruitment application, enabling the most human-relevant preclinical assessment of inflammatory bowel disease (IBD) drug candidates.
-
First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio
4/27/2022
First Wave BioPharma, Inc. announced the formation of a clinical steering committee focused on advancing the Company’s inflammatory bowel disease product portfolio, including FW-UP, FW-UC and FW-CD.
-
Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of a New Therapeutic Approach in Inflammatory Bowel Disease (IBD)
4/14/2022
Inotrem announced a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD.
-
Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Research
4/13/2022
Biomica Ltd. reported today that it signed a collaboration agreement with the Sheba Medical Center (Sheba) in Tel Aviv, Israel, a hospital ranked by Newsweek magazine as one of the top 10 globally of 2022[1].
-
Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)
2/24/2022
Second Genome yesterday hosted a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD), and a briefing on SG-5-00455, the Company's development candidate for the treatment of IBD.
-
Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of ECCO
2/18/2022
Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced preclinical data for SG-5-00455, the Company's development candidate.
-
Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23
2/14/2022
Second Genome today announced that it will host a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD) on Wednesday, February 23, 2022, from 12:00 – 1:00 p.m. EST.
-
Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)
2/10/2022
Second Genome today announced that the Company will advance SG-5-00455, which targets plasminogen activator inhibitor (PAI)-1/2, as a development candidate for the treatment of inflammatory bowel disease (IBD).
-
Takeda Canada Awards $1 Million To Support The Canadian IBD Research Consortium
2/3/2022
Crohn's and Colitis Canada is pleased to announce a $1 million PIONEER Grant from Takeda Canada, which will support the Canadian Inflammatory Bowel Disease Research Consortium.
-
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.